12月12日，由每日经济新闻主办的年度资本市场荣誉盛典评选结果出炉，上海益诺思生物技术股份有限 公司(股票代码：688710)凭借在社会责任领域的卓越实践与专业服务能力，荣膺"2025上市公司最具社 会责任奖"。这份荣誉不仅是对其企业担当的高度认可，更彰显了其在CRO专业细分领域的深厚积淀与 核心价值。 在创新驱动战略下，益诺思持续攻坚前沿技术，为业务增长注入持久动力。针对小核酸药物、CAR-T细 胞治疗等热门领域，公司建立了高灵敏度生物分析技术与多重生物标志物检测体系，形成了覆盖多品类 药物的技术服务矩阵，成为创新药研发企业的重要合作伙伴。 尤为值得关注的是,公司通过海外销售部，联动产业链上下游及产业资本合作伙伴搭建多元化营销渠 道，重点攻坚国际市场，海外市场新签订单金额同比大幅增长，国际市场认可度与品牌影响力持续提 升。益诺思已先后通过NMPA的GLP认证、美国FDA的GLP检查、OECD的GLP认证等多项权威资质， 服务网络覆盖全球700余家制药企业及科研机构。这种与国际标准接轨的服务能力，使其在海外市场竞 争中崭露头角，彰显了中国CRO企业的国际竞争力。 此次荣膺"最具社会责任奖"，既是对益诺思过往成 ...

证券之星消息，12月12日医疗服务板块较上一交易日上涨1.17%，益诺思领涨。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出2.4亿元，游资资金净流入1.35亿元，散户资金净 流入1.05亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | | 5.03 Z | 30.20% | -2.10 Z | -12.62% | -2.93 Z | -17.58% | | 300015 | 爰尔眼科 | | 5317.94万 | 8.82% | -6481.96万 | -10.74% | 1164.02万 | 1.93% | | 300759 | 康龙化成 | | 3575.66万 | 3.45% | -2598 ...

医药生物行业 行业研究 | 深度报告 融资明确上行，管线突破新高 ——CXO 景气度跟踪专题 核心观点 资金端：全球市场回暖，国内融资上行 1．一级市场：25Q3 拐点确立，全球和国内同步回暖，全年明确改善。 1）全球：触底后复苏动能增强，Q3 创近四年融资新高。全球医疗健康领域投融资 于 2021 年达到历史峰值，2022 年起逐步回落，2024 年触底，2025 年在波动中开启 复苏进程。从季度表现来看，25Q3 单季度融资额达 206 亿美元（+39%），创下近 4 年新高，全年回暖态势明确。 2）国内：与全球同步筑底反弹，势头更迅猛。国内医疗健康一级市场走势与全球基 本同步，21 年融资规模触及高点后，连续三年降温，25 年进入"先筑底、后反弹" 的上行通道。具体来看，25Q3 国内融资额达 182 亿元（+97%）；值得注意的是， 2025 年前 10 个月国内累计融资额已超过 2024 全年水平。 2．IPO：海外筑底，国内重启。放眼海外，NASDAQ 在 2020 年迎来生物科技公司 上市浪潮（融资高达 184 亿美元），21 年 IPO 数量再创新高（127 个）。随后，22 年 IPO 数量 ...

证券之星消息，12月5日医疗服务板块较上一交易日下跌0.03%，ST中珠领跌。当日上证指数报收于 3902.81，上涨0.7%。深证成指报收于13147.68，上涨1.08%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 10.77 | 10.01% | 51.19万 | 5.31亿 | | 920670 | 数字人 | 15.35 | 3.23% | 3.19万 | 4843.18万 | | 688710 | 益诺思 | 41.99 | 2.89% | 1.38万 | 5757.13万 | | 301096 | 百诚医药 | 54.49 | 2.48% | 2.61万 | 1.41亿 | | 301267 | 华屋眼科 | 18.90 | 2.27% | 6.22万 | 1.17亿 | | 002622 | 皓宸医疗 | 3.37 | 2.12% | 19.61万 | 6549.95万 | | 002173 | 创新医疗 | 22 ...

证券日报网讯12月2日，益诺思在互动平台回答投资者提问时表示，为遵循信息披露的公平原则，公司 会在定期报告中披露对应时点的股东信息。 ...

Core Viewpoint - The medical services sector experienced a decline of 2.05% on December 2, with Yinosh leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with ST Zhongzhu closing at 2.95, up 3.51%, and Yinosh closing at 41.58, down 7.27% [1][2]. - The total net outflow of main funds in the medical services sector was 9.53 billion yuan, while retail investors saw a net inflow of 6.87 billion yuan [2][3]. Group 2: Individual Stock Analysis - ST Zhongzhu had a trading volume of 1.27 million hands and a transaction amount of 372 million yuan, while Yinosh had a trading volume of 19,500 hands and a transaction amount of 82.48 million yuan [1][2]. - The stock performance varied, with some stocks like Innovation Medical and Dean Diagnostics showing slight declines, while others like ST Zhongzhu showed gains [1][2]. Group 3: Fund Flow Analysis - Main funds showed a net inflow in stocks like Innovation Medical (63.01 million yuan) and Dean Diagnostics (20.61 million yuan), while there were net outflows in several other stocks [3]. - Retail investors contributed to the net inflow in stocks like Innovation Medical and Dean Diagnostics, despite overall sector outflows [3].

Group 1 - The major shareholder, Zhangjiang Biopharmaceutical Base Development Co., Ltd., holds 11,020,753 shares, accounting for 7.82% of the total share capital of the company [1] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [1] - The reduction will be executed through centralized bidding, and the selling price will be determined by market conditions [1][2] Group 2 - The major shareholder has made commitments regarding the holding period and reduction methods, including a lock-up period of 12 months for shares held before the IPO and 36 months for shares obtained through capital increase [2][3] - The reduction plan is consistent with previous commitments made by the major shareholder [4] - The company confirms that the reduction will not lead to a change in control and will not significantly impact the company's ongoing operations [5]

Core Viewpoint - The company announced the appointment of two new vice presidents, Li Yan and Tang Napin, by the board of directors [1] Group 1 - The board of directors approved the hiring of Li Yan as vice president [1] - The board of directors approved the hiring of Tang Napin as vice president [1]

Core Points - Yinos's announcement on November 28 indicates that Zhangjiang Biopharmaceutical Base holds 11,020,753 shares of Yinos, representing 7.82% of the total share capital [2] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [2] - The reduction will be executed through centralized bidding and will not exceed 1.00% of the total shares within any consecutive 90-day period [2]

Group 1 - The company Yinos (SH 688710) announced plans to reduce its shareholding by up to approximately 1.41 million shares, which represents no more than 1% of the total share capital, within three months starting from 15 trading days after the announcement [1] - The share reduction will be conducted through centralized bidding, with the selling price determined by market conditions. Adjustments will be made to the reduction plan in case of any corporate actions such as dividends or stock splits during the implementation period [1] - As of the report, Yinos has a market capitalization of 6.3 billion yuan [1] Group 2 - For the fiscal year 2024, Yinos's revenue composition is as follows: non-clinical CRO accounts for 95.42%, clinical CRO accounts for 4.11%, other business segments account for 0.38%, and other operations account for 0.09% [1]